NCT00491985View on ClinicalTrials.gov

Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children

PHASE2CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

December 31, 2009

Study Completion Date

June 30, 2010

Conditions
InfluenzaOrthomyxoviridae InfectionsInfluenza A Virus Infection
Interventions
BIOLOGICAL

A/H5N1 Inactivated, split-virion pandemic influenza vaccine

0.5 mL, Intramuscular

BIOLOGICAL

A/H5N1 Inactivated, split virion pandemic influenza vaccine

0.5 mL, Intramuscular

BIOLOGICAL

A/H5N1 Inactivated, split virion pandemic influenza vaccine

0.25 mL, Intramuscular

Trial Locations (1)

Unknown

Bangkok

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00491985 - Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children | Biotech Hunter | Biotech Hunter